ArticleCell stem cell2026

Systemic delivery of phagocytosis-shielded retroviral vectors enables in vivo HSC gene therapy for sickle cell disease.

Denise Klatt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.